

ASX Announcement 9 June 2021

ELIXINOL WELLNESS TO EXPAND DISTRIBUTION IN AUSTRALIAN CBD MARKET AS IT CONTINUES TO DELIVER ON STRATEGY TO CREATE A GLOBAL, HEALTH AND WELLNESS CONSUMER PRODUCTS BUSINESS

- Health House to distribute Elixinol hemp derived CBD products in Australia under the Therapeutics Goods Administration's Special Access Scheme
- Agreement with Health House gives Elixinol access to Australia's 5700 pharmacies under the Special Access Scheme.
- Two products targeted to be in market by Q3
- **Distribution Agreement with PharmaCann terminated**

Elixinol Wellness Limited (Elixinol or the Company) (ASX:EXL; OTCQB:ELLXF) is pleased to announce that its wholly owned subsidiary Elixinol Wellness (Byron Bay) Pty Ltd has entered into an exclusive Supply & Distribution Agreement with HHI (Australia) Pty Ltd (HHI), a subsidiary of Health House International Limited (ASX:HHI) (Health House), to sell CBD products across Australia under the Therapeutics Goods Administration's (TGA's) Special Access Scheme (SAS). This is a significant milestone for the Company's growth strategy in Australia in light of the broad reach Health House has across Australasia within pharmacy channels and authorised medical practitioners. Up until March 2021, the TGA has approved over 100,000 patient applications for medical cannabis, and it is expected these numbers will grow.

The Elixinol and Health House Supply & Distribution Agreement (Agreement) enables Elixinol to import Elixinol branded CBD products from the US into Australia. The exclusive Agreement commences on 12 July 2021, has a two year term and as is usual in these types of agreements, the Agreement can be terminated mutually with 90 days written notice. There are no minimum purchase requirements under the Agreement and the Company cannot quantify expected orders over the term of the Agreement, however it represents continued execution of the Company's global strategy and will expand Elixinol's distribution of CBD products into Australia. The move will make Elixinol's high quality products available to patients via specialist and registered medical practitioners under the TGA's SAS or the Authorised Prescriber Scheme.



Health House International Limited (ASX: HHI) is an ASX listed international pharmaceutical distributor specialising in the distribution of medical cannabis products across Australasia, United Kingdom and Europe. HHI is one of Australia's major distributors of medicinal cannabis, with prescribers in all permissible states and has access to all 5700 national pharmacies.

In light of the Health House Agreement, Elixinol decided to terminate its distribution agreement with PharmaCann Pty Ltd (PharmaCann) announced to the market on 27 July 2020. Health House has greater reach across Australia with its established pharmacy distribution business and access to specialist prescribers. The contributions from the PharmaCann agreement have not been material to Elixinol's operations.

Global CEO, Oliver Horn, comments "We are very excited about partnering with Health House to bring our products to market here in Australia. A fast-growing number of patients are receiving help in the form of CBD via the TGA's Special Access Scheme and it is rewarding to know that soon our Elixinol products will make a contribution to people's wellbeing. Elixinol is well known for being an established quality brand and we can now satisfy demand for our products. This agreement delivers on our strategy to create a global wellness business by accessing the growing Australian market and utilising our Hemp Foods Australia business and corporate head office capabilities to grow our local business which already accounts for over a third of total Group revenues."

Health House Chief Operating Officer - Australasia, Paul Mavor said "Elixinol is one of the world's biggest CBD companies with a global footprint. Health House looks forward to supporting their range of medicines and hemp products in the Australian market."

This document was authorised to be given to the ASX by the Board of the Company.

Investor relations please contact:

Ron Dufficy, Global CFO ron.dufficy@elixinolwellness.com

About Elixinol Wellness

Elixinol Wellness Limited (ASX:EXL; OTCQB:ELLXF) is a global leader in the hemp industry, innovating, marketing and selling hemp derived nutraceutical, cosmetic and food products. The Company's simplified business model is focusing on:

- In the Americas, innovating, marketing and selling high quality Elixinol branded hemp derived nutraceutical and skincare products based in Colorado, USA
- In Europe and the UK, educating and selling high quality Elixinol branded and co-branded hemp derived nutraceutical and skincare products based in Utrecht, The Netherlands and London, UK



- In Australia, Hemp Foods Australia is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products
- Across the Rest of World, expanding distribution of Elixinol branded hemp derived products through reputable distributors as key markets open.

See more at www.elixinolwellness.com

About Health House

Health House International is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Company is a fully licenced and regulated specialised importer, exporter, consolidator and distributor of medicinal currently distributing 13+ medicinal cannabis products to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. With its Wholesale Dealers and Controlled Drugs licences the Company supplies pharmacies, hospital, government departments, veterinarians and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe.

See more at www.healthhouse.com